NASDAQ:MYOMyomo Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myomo, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.79 -0.02 (-0.52 %) (As of 06/2/2020 12:38 PM ET) Add Compare Share Today's Range$3.71Now: $3.79▼$3.8150-Day Range$3.73MA: $4.02▼$4.6052-Week Range$2.82Now: $3.79▼$40.00Volume1,034 shsAverage Volume575,309 shsMarket Capitalization$10.67 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Myomo, Inc., a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury. The company serves orthotics and prosthetics practices or clinics, as well as the veteran administration and other hospitals through orthotics and prosthetics providers, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Myomo. Previous Next 2.4 Community Rank Outperform VotesMyomo has received 51 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMyomo has received 57 “underperform” votes. (Add your “underperform” vote.)Community SentimentMyomo has received 52.78% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Myomo and other stocks. Vote “Outperform” if you believe MYO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMyomo does not currently pay a dividend.Dividend GrowthMyomo does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myomo insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MYO Previous Symbol CUSIPN/A CIKN/A Webwww.myomo.com Phone617-996-9058Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares2,814,000Market Cap$10.67 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:MYO Rates by TradingView Receive MYO News and Ratings via Email Sign-up to receive the latest news and ratings for MYO and its competitors with MarketBeat's FREE daily newsletter. Myomo (NASDAQ:MYO) Frequently Asked Questions How has Myomo's stock been impacted by COVID-19 (Coronavirus)? Myomo's stock was trading at $4.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MYO shares have decreased by 19.0% and is now trading at $3.79. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Myomo? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myomo in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myomo. When is Myomo's next earnings date? Myomo is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Myomo. How were Myomo's earnings last quarter? Myomo, Inc. (NASDAQ:MYO) posted its quarterly earnings data on Thursday, March, 12th. The company reported ($4.81) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($4.48) by $0.33. The company earned $1.52 million during the quarter, compared to the consensus estimate of $1.40 million. View Myomo's earnings history. Has Myomo been receiving favorable news coverage? News headlines about MYO stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myomo earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMyomo. Who are some of Myomo's key competitors? Some companies that are related to Myomo include Polarean Imaging (POLX), Respiri (RSH), Anteo Diagnostics (ADO), Universal Biosensors (UBI), Helius Medical Technologies (HSM), Oventus Medical (OVN), LBT Innovations (LBT), Impedimed (IPD), Titan Medical (TMD), Inspiration Healthcare Group (IHC), Azure Healthcare (AZV), Heramed (HMD), Analytica (ALT), Surgical Innovations Group (SUN) and Xtant Medical (XTNT). View all competitors. What other stocks do shareholders of Myomo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myomo investors own include Cocrystal Pharma (COCP), Amgen (AMGN), AbbVie (ABBV), American Airlines Group (AAL), Becton Dickinson and (BDX), Chevron (CVX), E I Du Pont De Nemours And Co (DD), Walt Disney (DIS), Dow Chemical (DOW) and Ford Motor (F). Who are Myomo's key executives? Myomo's management team includes the following people: Mr. Paul R. Gudonis, Chairman, Pres & CEO (Age 63)Ms. Davie Mendelsohn RN, VP of Sales & Clinical Services (Age 64)Mr. Jonathan Naft, VP & GM (Age 53)Mr. Ralph A. Goldwasser, Chief Financial Officer (Age 70)Mr. Clifford J. Conneighton, Chief Marketing Officer (Age 68) What is Myomo's stock symbol? Myomo trades on the NASDAQ under the ticker symbol "MYO." How do I buy shares of Myomo? Shares of MYO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Myomo's stock price today? One share of MYO stock can currently be purchased for approximately $3.79. How big of a company is Myomo? Myomo has a market capitalization of $10.67 million. What is Myomo's official website? The official website for Myomo is www.myomo.com. How can I contact Myomo? The company can be reached via phone at 617-996-9058. This page was last updated on 6/2/2020 by MarketBeat.com Staff
